Remoxipride Explained

Remoxipride (Roxiam) is an atypical antipsychotic (although according to some sources it is a typical antipsychotic) which was previously used in Europe for the treatment of schizophrenia and acute mania but was withdrawn due to toxicity concerns (incidence of aplastic anemia in 1/10,000 patients).^[1] It was initially launched by AstraZeneca in 1990 and suspension of its use began in 1993.^[1] Remoxipride acts as a selective D₂ and D₃ receptor antagonist and also has high affinity for the sigma receptor, possibly playing a role in its atypical neuroleptic action.^[2]

Due to its short half-life twice daily (bid) dosing is required, although a once-daily controlled-release tablet has been developed.^[3] There was some interest in its use in the treatment of treatment-resistant schizophrenia.^{[4] [5]}

See also

• Typical antipsychotic
• Benzamide

External links

• Herbert Y. Meltzer, Atypical Antipsychotic Drugs, 2000

Notes and References

1. Book: Vela JM, Buschmann H, Holenz J, Párraga A, Torrens A . Antidepressants, Antipsychotics, Anxiolytics: From Chemistry and Pharmacology to Clinical Application . Wiley-VCH . Weinheim . 2007 . 978-3-527-31058-6 .
2. Köhler C, Hall H, Magnusson O, Lewander T, Gustafsson K . Biochemical pharmacology of the atypical neuroleptic remoxipride . Acta Psychiatrica Scandinavica. Supplementum . 358 . 27–36 . 1990 . 1978484 . 10.1111/j.1600-0447.1990.tb05282.x . 144567193 .
3. Alexander MS, Chakravarti SK, Sundararajan K, Mullin JM, Shaw SH, Blomqvist M, Lockett CM . Once-daily controlled release remoxipride is equieffective with twice-daily immediate release remoxipride in the treatment of schizophrenia . Journal of Psychopharmacology . 7 . 3 . 276–82 . January 1993 . 22290842 . 10.1177/026988119300700307 . 23518319 .
4. Remoxipride therapy in treatment resistant schizophrenia. Conley R, Dixon L, Nguyen JA, Tamminga C, Raymond R . 10.1016/0920-9964(93)90521-J . April 1993 . 9 . 2–3 . Schizophrenia Research. 235–236. 54386181 .
5. Remoxipride therapy in poorly responsive schizophrenics. Conley R, Dixon L, Nguyen JA, Tamminga C, Raymond R . 10.1016/0920-9964(91)90208-9 . April 1993 . 4 . 3 . 316 . Schizophrenia Research . 54317014 .